Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-29), Voyager Therapeutics's 3-1 Month Momentum % is -3.60%.
The industry rank for Voyager Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
FRA:VT6's 3-1 Month Momentum % is ranked better than 58.9% of 1387
companies
in the Biotechnology industry
Industry Median: -10.62
vs FRA:VT6: -3.60
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Voyager Therapeutics 3-1 Month Momentum % Related Terms
FRA:VT6 vs NERV, DTIL, GLSI: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Voyager Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyager Therapeutics (FRA:VT6) has a 3-1 Month Momentum % of -3.60% as of Jul. 29, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Voyager Therapeutics and its competitors. According to the industry distribution chart, Voyager Therapeutics ranks #570 out of 1387 companies in the Biotechnology industry, placing it in the top 41.1%.
Is Voyager Therapeutics' 3-1 Month Momentum % too high?
Voyager Therapeutics' current 3-1 Month Momentum % is -3.60%. Based on the distribution chart, Voyager Therapeutics ranks #570 out of 1387 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Voyager Therapeutics has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' 3-1 Month Momentum % compare to NERV and DTIL?
According to the Biotechnology industry distribution chart, Voyager Therapeutics ranks #570 out of 1387 companies for 3-1 Month Momentum %. This puts Voyager Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current 3-1 Month Momentum % is -3.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.42, compared to a current price of €2.58 — trading 81.4% above its estimated fair value. The current 3-1 Month Momentum % is -3.60%. Voyager Therapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current 3-1 Month Momentum % is -3.60% as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?
Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued.
The current stock price of €2.58 is trading 81.4% above its estimated GF Value™ of €1.42.
GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:VT6:
3-1 Month Momentum %: -3.60%
GF Value™: €1.42 vs. price of €2.58 (81.4% above fair value)
No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
54GF Score
Get the complete analysis for FRA:VT6
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VT6 has been successfully added to your 
